Abstract:Background: Previous studies reported on the existence of atrophy-based Alzheimer's disease (AD) subtypes that associate with distinct clinical symptoms. However, the consistency of AD atrophy subtypes across approaches remains uncertain. This large-scale study aims to assess subtype concordance in individuals using two methods of data-driven subtyping. Methods: We included n=10,011 patients across the clinical spectrum from 10 AD cohorts across Europe, United States, and Australia, and extracted regional volumes using Freesurfer v7.1.1. To characterise atrophy heterogeneity in the AD continuum, we introduced a hybrid two-step approach called Snowphlake (Staging NeurOdegeneration With PHenotype informed progression timeLine of biomarKErs) to identify subtypes and sequence of atrophy-events within each subtype. We compared our results with SuStaIn (Subtype and Stage Inference) which jointly estimates both, and was trained and validated similarly. The training dataset included Aβ+ participants (n=1,195), and a control group of Aβ- cognitively unimpaired participants (n=1,692). We validated model staging within each subtype, in a held-out clinical-validation dataset (n=6,362) comprising patients across the clinical spectrum irrespective of Aβ biomarker status and an independent external dataset (n=762). Furthermore, we validated the clinical significance of the detected subtypes, in a subset of Aβ+ validation datasets with n=1,796 in the held-out sample and n=159 in the external dataset. Lastly, we performed concordance analysis to assess the consistency between the methods. Results: In the AD dementia (AD-D) training data, Snowphlake identified four subtypes: diffuse cortical atrophy (21.1%,age 67.5±9.3), parieto-temporal atrophy (19.8%,age 60.9±7.9), frontal atrophy (24.8%,age 67.6±8.8) and subcortical atrophy (25.1%,68.3±8.2). The subtypes assigned in Aβ+ validation datasets were associated with alterations in specific cognitive domains (Cohen's f: [0.15-0.33]), while staging correlated with Mini-Mental State Examination (MMSE) scores (R: [-0.51 to -0.28]) in the validation datasets. SuStaIn also identified four subtypes: typical (55.7%,age 66.7±7.8), limbic-predominant (24.2%,age 72.2±6.6), hippocampal-sparing (14.6%,age 62.8±6.9), and subcortical (0.8%,age 68.2±7.6). The subtypes assigned in Aβ+ validation datasets using SuStaIn were also associated with alterations in specific cognitive domains (Cohen's f:[0.17-0.34]), while staging correlated with MMSE scores in the validation datasets (R: [-0.54 to -0.26]). However, we observed low concordance between Snowphlake and SuStaIn, with 39.7% of AD-D patients consistently grouped in concordant subtypes by both the methods. Conclusion: In this multi-cohort study, both Snowphlake and SuStaIn identified four subtypes that were associated with different symptom profiles and atrophy-severity measures that were associated with global cognition. The low concordance between Snowphlake and SuStaIn suggests that heterogeneity may rather be a spectrum than discretised by subtypes.

How reproducible are data-driven subtypes of Alzheimer's disease atrophy?

A large-scale multi-centre study characterising atrophy heterogeneity in Alzheimer's disease

Alzheimer‐like biomarker heterogeneity in a preclinical elderly birth cohort: Insight46

Inter-Cohort Validation of SuStaIn Model for Alzheimer’s Disease

Multimodal subtypes identified in Alzheimer's Disease Neuroimaging Initiative participants by missing-data-enabled subtype and stage inference

A generalizable data-driven model of atrophy heterogeneity and progression in memory clinic settings

Disentangling the heterogeneity of brain atrophy in Alzheimer’s Disease

Delineating three distinct spatiotemporal patterns of brain atrophy in Parkinson's disease

Distinct Spontaneous Brain Activity Patterns in Different Biologically-Defined Alzheimer's Disease Cognitive Stage: A Preliminary Study.

Pathologic subtyping of Alzheimer's disease brain tissue reveals disease heterogeneity

Heterogeneity of Regional Brain Atrophy Patterns Associated with Distinct Progression Rates in Alzheimer’s Disease

Identification of Outcome-Oriented Progression Subtypes from Mild Cognitive Impairment to Alzheimer’s Disease Using Electronic Health Records

Resolving heterogeneity in Alzheimer's disease based on individualized structural covariance network

Disease staging of Alzheimer's disease using a CSF-based biomarker model

Four distinct subtypes of Alzheimer's disease based on resting-state connectivity biomarkers

Four Distinct Subtypes of Alzheimer’s Disease Based on Resting-State Connectivity Biomarkers

Discovering Alzheimer’s Disease Subtypes with Imaging and Genetic Signatures Via Multi‐view Weakly‐supervised Deep Clustering

Pathology Steered Stratification Network for Subtype Identification in Alzheimer's Disease

Data-driven neuroanatomical subtypes of primary progressive aphasia

Grab‐AD: Generalizability and Reproducibility of Altered Brain Activity and Diagnostic Classification in Alzheimer's Disease

Identifying and evaluating clinical subtypes of Alzheimer’s disease in care electronic health records using unsupervised machine learning